Data Access and Future Directions
The study recognizes that current sample size limits generalizability. Newborn screening studies are planned to validate recessive disorder risk estimates. Researchers can request data access through HKGI review if they have institutional…
1 sources - 5 claims
The study recognizes that current sample size limits generalizability. Newborn screening studies are planned to validate recessive disorder risk estimates. Researchers can request data access through HKGI review if they have institutional review board approval. Wider access to individual-level genomic data is planned after completion of the main phase in 2030. Future plans include long-read sequencing, multiomics, improved bioinformatics, clinical decision support, and pragmatic trials.